Sign In
Buy MREO
$0.334
-0.0052 (-1.53%)
At Close: Jun 03, 2026
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced the successful completion of a Type B
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
12:21pm, Wednesday, 19'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
08:00am, Wednesday, 19'th Feb 2020
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Securities Purchase Agreement (the “Agreement”) with a new U.S.-based insti
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More
01:41pm, Friday, 14'th Feb 2020
Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it is distributing approximately 1.2 cents cash per Contingent Value Right (“CVR”), a total of ap
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN )
TSLA, INO among premarket gainers
02:16pm, Monday, 10'th Feb 2020
vTv Therapeutics (NASDAQ:VTVT) +80% on positive TTP399 data.Taubman Centers (NYSE:TCO) +52% on being acquired by Simon Property Group.Edgewell Personal Care (NYSE:EPC) +21% after Q4 results.Mereo B
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced additional endpoint data from the Company’s Phase 2b dose-ranging "ASTEROID" clinical study of setrusuma
Mid-Day Market Update: Crude Oil Down Over 1%; Dare Bioscience Shares Spike Higher
05:27pm, Monday, 13'th Jan 2020
Midway through trading Monday, the Dow traded up 0.20% to 28881.58 while the NASDAQ rose 0.49% to 9223.50. The S&P also rose, gaining 0.38% to 3277.76.
Leading and Lagging...
Mid-Morning Market Update: Markets Open Higher; Cott To Acquire Primo Water
03:25pm, Monday, 13'th Jan 2020
Following the market opening Monday, the Dow traded up 0.07% to 28,844.56 while the NASDAQ rose 0.38% to 9,213.47. The S&P also rose, gaining 0.26% to 3,273.88.
Leading and...
DDD, NVTA among premarket gainers
02:27pm, Monday, 13'th Jan 2020
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors.Verona Pharma PLC (NASDAQ:VRNA) +54% on positive ensifentrine data.Mereo BioP
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
12:00pm, Monday, 13'th Jan 2020
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," and Oncologie, Inc. (“Oncologie”) today announced a global license agreement (the “License Agreement”) for the dev
Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," today announces 12-month topline data from the Company's Phase 2b dose-ranging "ASTEROID" clinical study of
Mereo BioPharma Sees Hammer Chart Pattern: Time to Buy?
12:18pm, Wednesday, 09'th Oct 2019
Mereo BioPharma has been struggling lately, but the selling pressure may be coming to an end soon.
